Literature DB >> 25231404

Calreticulin promotes migration and invasion of esophageal cancer cells by upregulating neuropilin-1 expression via STAT5A.

Feng Shi1, Li Shang1, Bei-Qing Pan1, Xiao-Min Wang1, Yan-Yi Jiang1, Jia-Jie Hao1, Yu Zhang1, Yan Cai1, Xin Xu1, Qi-Min Zhan1, Ming-Rong Wang2.   

Abstract

PURPOSE: We previously revealed that the calreticulin (CRT) gene is a candidate oncogene promoting cell migration and invasion and that neuropilin-1 (NRP1) is a possible effector downstream of CRT in esophageal squamous carcinoma cells. This study aims to explore the mechanisms underlying the migration and invasion of esophageal cancer cells regulated by CRT through NRP1. EXPERIMENTAL
DESIGN: Quantitative reverse-transcription polymerase chain reaction, Western blot analysis, chromatin immunoprecipitation, and reporter gene assays were used to investigate the relationship between CRT and NRP1. In vitro and in vivo assays were carried out to evaluate the effects of NRP1 on malignant phenotypes of ESCC cells and tumor metastasis in NOD/SCID mice. Immunohistochemistry was performed to analyze the expression of CRT and NRP1 in esophageal squamous cell carcinomas (ESCC).
RESULTS: Knockdown of CRT decreased the expression of NRP1. Inhibition of NRP1 reduced ESCC cell motility in vitro and experimental metastasis in vivo. Ectopic expression of NRP1 rescued the defects of cell migration and invasion in CRT-shRNA cells. CRT depletion inhibited STAT5A phosphorylation at the Y694 site via a CaMKII-independent pathway. Moreover, STAT5A directly regulated NRP1 transcription. Knockdown of CRT or NRP1 led to a downregulation of MMP2, MMP9, and FAK. Notably, positive correlation was found between CRT and NRP1 expression in ESCC tissues (P = 5.87 × 10(-5)). CRT and NRP1 coexpression was significantly associated with lymph node metastasis (P = 0.025).
CONCLUSIONS: Our findings suggest that NRP1 is a critical downstream effector of CRT in promoting cell migration and invasion, which might contribute to the metastasis of ESCC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25231404     DOI: 10.1158/1078-0432.CCR-14-0583

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Calreticulin Regulates Neointima Formation and Collagen Deposition following Carotid Artery Ligation.

Authors:  Kurt A Zimmerman; Dongqi Xing; Manuel A Pallero; Ailing Lu; Masahito Ikawa; Leland Black; Kenneth L Hoyt; Janusz H Kabarowski; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2016-02-25       Impact factor: 1.934

2.  HIF-1-regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation.

Authors:  Xiaoxu Liu; Peiling Xie; Na Hao; Miao Zhang; Yang Liu; Peijun Liu; Gregg L Semenza; Jianjun He; Huimin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-02       Impact factor: 11.205

3.  Calreticulin nuclear translocalization alleviates CaM/CaMKII/CREB signaling pathway to enhance chemosensitivity in HDAC inhibitor-resistant hepatocellular carcinoma cells.

Authors:  Yi-Sheng Liu; Yu-Chun Chang; Wei-Wen Kuo; Ming-Cheng Chen; Tso-Fu Wang; Tung-Sheng Chen; Yueh-Min Lin; Chi-Cheng Li; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Aging (Albany NY)       Date:  2022-06-20       Impact factor: 5.955

4.  Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation.

Authors:  F Shi; L Shang; L-Y Yang; Y-Y Jiang; X-M Wang; J-J Hao; Y Zhang; D-K Huang; Y Cai; X Xu; Q-M Zhan; X-M Jia; Y Cao; M-R Wang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

5.  Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.

Authors:  Christopher A Chuckran; Anthony R Cillo; Jessica Moskovitz; Abigail Overacre-Delgoffe; Ashwin S Somasundaram; Feng Shan; Grant C Magnon; Sheryl R Kunning; Irina Abecassis; Amer H Zureikat; James Luketich; Arjun Pennathur; John Sembrat; Mauricio Rojas; Daniel T Merrick; Sarah E Taylor; Brian Orr; Francesmary Modugno; Ron Buckanovich; Robert E Schoen; Seungwon Kim; Umamaheswar Duvvuri; Herbert Zeh; Robert Edwards; John M Kirkwood; Lan Coffman; Robert L Ferris; Tullia C Bruno; Dario A A Vignali
Journal:  Sci Transl Med       Date:  2021-12-08       Impact factor: 19.319

6.  Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small cell lung cancer.

Authors:  Ke Wang; Hao Li; Ruo Chen; Yang Zhang; Xiu-Xuan Sun; Wan Huang; Huijie Bian; Zhi-Nan Chen
Journal:  Oncotarget       Date:  2017-06-16

7.  Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.

Authors:  Duthika M Mallawaaratchy; Susannah Hallal; Ben Russell; Linda Ly; Saeideh Ebrahimkhani; Heng Wei; Richard I Christopherson; Michael E Buckland; Kimberley L Kaufman
Journal:  J Neurooncol       Date:  2016-10-21       Impact factor: 4.130

8.  Calreticulin down-regulation inhibits the cell growth, invasion and cell cycle progression of human hepatocellular carcinoma cells.

Authors:  Ruo Feng; Jianwen Ye; Chuang Zhou; Lei Qi; Zhe Fu; Bing Yan; Zhiwei Liang; Renfeng Li; Wenlong Zhai
Journal:  Diagn Pathol       Date:  2015-08-27       Impact factor: 2.644

9.  5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway.

Authors:  Hua Sui; Hanchen Xu; Qing Ji; Xuan Liu; Lihong Zhou; Haiyan Song; Xiqiu Zhou; Yangxian Xu; Zhesheng Chen; Jianfeng Cai; Guang Ji; Qi Li
Journal:  Oncotarget       Date:  2015-09-22

10.  Calreticulin is highly expressed in pancreatic cancer stem-like cells.

Authors:  Satoshi Matsukuma; Kiyoshi Yoshimura; Tomio Ueno; Atsunori Oga; Moeko Inoue; Yusaku Watanabe; Atsuo Kuramasu; Masanori Fuse; Ryouichi Tsunedomi; Satoshi Nagaoka; Hidetoshi Eguchi; Hiroto Matsui; Yoshitaro Shindo; Noriko Maeda; Yoshihiro Tokuhisa; Reo Kawano; Tomoko Furuya-Kondo; Hiroshi Itoh; Shigefumi Yoshino; Shoichi Hazama; Masaaki Oka; Hiroaki Nagano
Journal:  Cancer Sci       Date:  2016-11-04       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.